TRAW insider transaction filings
Traws Pharma, Inc. — 47 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-16. Screen TRAW transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-16 | 4 | Pauza Charles David — Chief Science Officer Virology | Grant/award (A): 97,000 (derivative) @ $0 | EDGAR |
| 2026-07-15 | 4 | Savchuk Nikolay — Chief Operating Officer, Director | Grant/award (A): 93,000 (derivative) @ $0 | EDGAR |
| 2026-07-15 | 4 | CAUTREELS WERNER — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Parker Charles Nolan — Chief Financial Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Redfield Robert — Chief Medical Officer | Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Clarke Trafford — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Shoemaker Mary Teresa — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Dukes Iain D. — Chief Executive Officer, Director | Grant/award (A): 274,000 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Leaman John Harold — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | STOVER JACK E — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VIII LLC — 10% owner | Purchase (P): 597,729 @ $1.67 · Purchase (P): 597,729 (derivative) · Purchase (P): 597,729 (derivative) · Purchase (P): 1,793,187 (derivative) | EDGAR |
| 2026-04-08 | 4 | Parker Charles Nolan — Chief Financial Officer | Grant/award (A): 15,393 @ $0 · Grant/award (A): 32,406 (derivative) @ $0 · Grant/award (A): 61,571 (derivative) @ $0 · Grant/award (A): 104,544 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Redfield Robert — Chief Medical Officer | Grant/award (A): 108,854 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Pauza Charles David — Chief Science Officer Virology | Grant/award (A): 118,367 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Savchuk Nikolay — Chief Operating Officer, Director | Grant/award (A): 96,899 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Clarke Trafford — Director | Grant/award (A): 33,435 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Shoemaker Mary Teresa — Director | Grant/award (A): 33,435 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Dukes Iain D. — Chief Executive Officer, Director | Grant/award (A): 231,336 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Leaman John Harold — Director | Grant/award (A): 33,435 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | CAUTREELS WERNER — Director | Grant/award (A): 31,258 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | STOVER JACK E — Director | Grant/award (A): 33,435 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Redfield Robert — Chief Medical Officer | Grant/award (A): 16,419 @ $0 · Grant/award (A): 65,676 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Pauza Charles David — Chief Science Officer Virology | Grant/award (A): 18,471 @ $0 · Grant/award (A): 73,886 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Savchuk Nikolay — Chief Operating Officer, Director | Grant/award (A): 16,419 @ $0 · Grant/award (A): 65,676 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Clarke Trafford — Director | Grant/award (A): 6,157 @ $0 · Grant/award (A): 24,629 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Shoemaker Mary Teresa — Director | Grant/award (A): 6,157 @ $0 · Grant/award (A): 24,629 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Dukes Iain D. — Chief Executive Officer, Director | Grant/award (A): 36,943 @ $0 · Grant/award (A): 147,771 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Leaman John Harold — Director | Grant/award (A): 4,058 @ $0 · Grant/award (A): 16,234 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | CAUTREELS WERNER — Director | Grant/award (A): 4,874 @ $0 · Grant/award (A): 19,496 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | STOVER JACK E — Director | Grant/award (A): 6,157 @ $0 · Grant/award (A): 24,629 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Leaman John Harold — Director | Grant/award (A): 12,770 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Clarke Trafford — Director | Grant/award (A): 11,530 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Redfield Robert — Chief Medical Officer | Grant/award (A): 32,406 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Pauza Charles David — Chief Science Officer Virology | Grant/award (A): 32,406 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Savchuk Nikolay — Chief Operating Officer, Director | Grant/award (A): 22,435 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Shoemaker Mary Teresa — Director | Grant/award (A): 11,530 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Dukes Iain D. — Chief Executive Officer, Director | Grant/award (A): 64,839 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | CAUTREELS WERNER — Director | Grant/award (A): 11,530 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | STOVER JACK E — Director | Grant/award (A): 11,530 (derivative) @ $0 | EDGAR |
| 2025-10-14 | 4 | Leaman John Harold — Director | Grant/award (A): 15,609 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Clarke Trafford — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | STOVER JACK E — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Shoemaker Mary Teresa — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | CAUTREELS WERNER — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2025-04-08 | 4 | TPAV, LLC — 10% owner Savchuk Nikolay — Chief Operating Officer, 10% owner | Other (J): 605,531 · Other (J): 2,263.75 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | CAUTREELS WERNER — Chief Executive Officer, Director | Option exercise (M): 96,348 @ $0.01 · Option exercise (M): 96,348 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Guerin Mark Patrick — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
Recent 8-K events — Traws Pharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-07-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-15 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TRAW returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →